TY - GEN
T1 - Therapeutic interruption of advanced glycation in diabetic nephropathy
T2 - Do all roads lead to Rome?
AU - Sourris, Karly C.
AU - Forbes, Josephine M.
AU - Cooper, Mark E.
PY - 2008/4
Y1 - 2008/4
N2 - A major common feature of the chemically disparate compounds that inhibit advanced glycation end product (AGE) accumulation or signaling is their ability to show end-organ protection in experimental models of diabetes complications. The mechanisms by which these AGE- lowering therapies confer their benefits remain unsolved. Is it the reduction in tissue AGE levels per se or the inhibition of downstream signal transduction (as has been described with the soluble receptor for AGE)? Possible modes of action that need to be investigated include the ability of some of these agents to stimulate antioxidant defenses, to lower cholesterol and other lipid levels, and to inhibit low-grade inflammation. To understand these novel mechanisms, further examination of the advanced glycation pathway and, in particular, the diverse action of these agents in ameliorating the development of diabetic complications is needed.
AB - A major common feature of the chemically disparate compounds that inhibit advanced glycation end product (AGE) accumulation or signaling is their ability to show end-organ protection in experimental models of diabetes complications. The mechanisms by which these AGE- lowering therapies confer their benefits remain unsolved. Is it the reduction in tissue AGE levels per se or the inhibition of downstream signal transduction (as has been described with the soluble receptor for AGE)? Possible modes of action that need to be investigated include the ability of some of these agents to stimulate antioxidant defenses, to lower cholesterol and other lipid levels, and to inhibit low-grade inflammation. To understand these novel mechanisms, further examination of the advanced glycation pathway and, in particular, the diverse action of these agents in ameliorating the development of diabetic complications is needed.
KW - Advanced glycation end products
KW - Diabetic nephropathy
KW - Reactive oxygen species
KW - Receptor for advanced glycation end products
UR - http://www.scopus.com/inward/record.url?scp=42549110364&partnerID=8YFLogxK
U2 - 10.1196/annals.1433.048
DO - 10.1196/annals.1433.048
M3 - Conference Paper
C2 - 18448801
AN - SCOPUS:42549110364
SN - 9781573317
SN - 9789781573316
T3 - Annals of the New York Academy of Sciences
SP - 101
EP - 106
BT - The Maillard Reaction Recent Advances in Food and Biomedical Sciences
PB - Wiley-Blackwell
ER -
